Pathologic Complete Response With Six Compared With Three Cycles of Neoadjuvant Epirubicin Plus Docetaxel and Granulocyte Colony-Stimulating Factor in Operable Breast Cancer: Results of ABCSG-14
Authors:
- Günther G. StegerGSGünther G. Steger
- Arik GalidAGArik Galid
- Michael GnantMichael Gnant
- Brigitte MlineritschBMBrigitte Mlineritsch
- Alois LangALAlois Lang
- Christoph TauschCTChristoph Tausch
- Margaretha RudasMRMargaretha Rudas
- Richard GreilRGRichard Greil
- Catharina WenzelCWCatharina Wenzel
- Christian F. SingerCSChristian F. Singer
- Anton HaidAHAnton Haid
- Sabine PöstlbergerSPSabine Pöstlberger
- 20 May 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (15) , 2012-2018
Abstract
Purpose: Preoperative (neoadjuvant) chemotherapy for operable breast cancer downstages tumors initially not suitable for breast-conserving surgery. A pathologic complete response (pCR) to neoadjuvant chemotherapy may be a surrogate for longer overall survival, but this beneficial effect remains to be established. This phase III trial evaluated whether doubling the number of cycles of neoadjuvant treatment increased the pCR rate. Patients and Methods: Patients with biopsy-proven breast cancer (T1-4a-c, N±, M0; stage I to III) were eligible and randomly assigned to either three or six cycles of epirubicin 75 mg/m2 and docetaxel 75 mg/m2 on day 1 and granulocyte colony-stimulating factor on days 3 through 10 (ED+G), every 21 days. The primary end point was the pCR rate of the breast tumor. Secondary end points were pathologic nodal status after surgery and the rate of breast-conserving surgery. Results: A total of 292 patients were accrued, and 288 patients were assessable for efficacy and safety. Groups were well balanced for known prognostic factors. Six cycles of ED+G, compared with three cycles, resulted in a significantly higher pCR rate (18.6% v 7.7%, respectively; P = .0045), a higher percentage of patients with negative axillary status (56.6% v 42.8%, respectively; P = .02), and a trend towards more breast-conserving surgery (75.9% v 66.9%, respectively; P = .10). Rates of adverse events were similar, and no patients died on treatment. Conclusion: Doubling the number of neoadjuvant ED+G cycles from three to six results in higher rates of pCR and negative axillary nodal status with no excess of adverse effects. Thus, six cycles of ED+G should be the standard neoadjuvant treatment for operable breast cancer if this combination is chosen.Keywords
This publication has 18 references indexed in Scilit:
- Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2006
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast CancerJournal of Clinical Oncology, 2005
- In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot studyAnnals of Oncology, 2005
- Randomized Parallel Study of Doxorubicin Plus Paclitaxel and Doxorubicin Plus Cyclophosphamide As Neoadjuvant Treatment of Patients With Breast CancerJournal of Clinical Oncology, 2004
- Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center ExperienceJournal of Clinical Oncology, 2004
- Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter StudyJournal of Clinical Oncology, 2003
- The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cellsOncogene, 1997
- Neoadjuvant Chemotherapy Enables Breast-Conserving Surgery in Patients with Very Large Breast Cancers: Preliminary ResultsOncology Research and Treatment, 1996
- Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6European Journal of Cancer, 1994
- Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or MoreJNCI: Journal of the National Cancer Institute, 1990